China to Impose Tariffs of 34% on All US Goods from April 10

Reuters
昨天

BEIJING, April 4 (Reuters) - China on Friday announced a slew of countermeasures against tariffs imposed by President Donald Trump, including additional tariffs of 34% on all U.S. goods and curbs on export of some rare earths, deepening an escalating trade war.

China's finance ministry said the additional tariffs would be imposed from April 10.

Trump on Wednesday announced that China would be hit with a 34% tariff, on top of the 20% he imposed earlier this year, bringing the total new levies to 54%.

Agriculture trade took another hit as Chinese customs imposed an immediate suspension on imports of sorghums from grain exporter C&D (USA) Inc., as well as poultry and bonemeal from three U.S. firms.

Beijing also announced controls on exports of medium and heavy rare-earths, including samarium, gadolinium, terbium, dysprosium, lutetium, scandium and yttrium to the United States, effective April 4.

"The purpose of the Chinese government's implementation of export controls on relevant items in accordance with the law is to better safeguard national security and interests, and to fulfil international obligations such as non-proliferation," the commerce ministry said in a statement.

It also added 16 U.S entities to its export control list, which prohibits the export of dual-use items to affected firms.

Another 11 U.S. firms were added to the "unreliable entities" list, which allows Beijing to take punitive action against foreign entities. The targeted firms includes Skydio Inc. and BRINC Drones over arms sales to democratically governed Taiwan, which China claims as part of its territory.

The commerce ministry said the targeted companies seriously "undermined" China's national sovereignty, security and development interests and would be prohibited from new investments, import and export activities in China.

It also launched an anti-dumping probe into imports of certain medical CT tubes from the U.S. and India, and a wider industry competitiveness investigation into imports of medical CT tubes.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10